Please login to the form below

Not currently logged in
Email:
Password:

FDA calls for expanded Byetta precautions

The FDA has revealed it suspects a link between usage of Byetta (exenatide injection), a type 2 diabetes drug, and acute pancreatitis.

The FDA has revealed it suspects a link between usage of Byetta (exenatide injection), a type 2 diabetes drug, and acute pancreatitis.

The FDA said it reviewed 30 reports of acute pancreatitis in patients taking Byetta and added: "An association between Byetta and acute pancreatitis is suspected in some of these cases."

Officials said the maker of Byetta, Amylin, has agreed to include information about acute pancreatitis in the precautions section of the product's label.

"Healthcare professionals should be alert to the signs and symptoms of acute pancreatitis and instruct patients taking Byetta to seek prompt medical care if they experience unexplained, persistent, severe abdominal pain which may or may not be accompanied by vomiting," the FDA said.

On 10 October 2007, Amylin's co-marketing partner Lilly launched Byetta in India. India becomes the fourth major launch in the world after the US, UK and Germany where Byetta is now available.

30th September 2008

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Bedrock Healthcare Communications

Bedrock Healthcare Communications is a privately owned, award winning communications agency that creates and delivers highly effective, insight driven medical...

Latest intelligence

Brain power: fresh approaches to Alzheimer’s drug discovery
New alliances are learning from past mistakes and breaking down research barriers...
Genomics integration: can the NHS rise to the challenge?
Experts gather to discuss the UK’s genomic landscape...
London
“Brexit has been a catalyst for UK clinical research... it’s turbocharged change”
The UK clinical trials environment has been transformed in recent years – but can it really buck Brexit’s risks and uncertainties?...

Infographics